1
|
Galffy G, Lugowska I, Poddubskaya EV, Cho BC, Ahn MJ, Han JY, Su WC, Hauke RJ, Dyar SH, Lee DH, Serwatowski P, Estelles DL, Holden VR, Kim YJ, Vladimirov V, Horvath Z, Ghose A, Goldman A, di Pietro A, Wang J, Murphy DA, Alhadab A, Laskov M. A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer. ESMO Open 2023; 8:101173. [PMID: 37141847 DOI: 10.1016/j.esmoop.2023.101173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2022] [Revised: 01/17/2023] [Accepted: 02/06/2023] [Indexed: 05/06/2023] Open
Abstract
BACKGROUND We hypothesized that avelumab plus axitinib could improve clinical outcomes in patients with advanced non-small-cell lung cancer (NSCLC) or urothelial carcinoma (UC). PATIENTS AND METHODS We enrolled previously treated patients with advanced or metastatic NSCLC, or untreated, cisplatin-ineligible patients with advanced or metastatic UC. Patients received avelumab 800 mg every 2 weeks (Q2W) and axitinib 5 mg orally two times daily. The primary endpoint was objective response rate (ORR). Immunohistochemistry was used to assess programmed death-ligand 1 (PD-L1) expression (SP263 assay) and the presence of CD8+ T cells (clone C8/144B). Tumor mutational burden (TMB) was assessed by whole-exome sequencing. RESULTS A total of 61 patients were enrolled and treated (NSCLC, n = 41; UC, n = 20); 5 remained on treatment at data cut-off (26 February 2021). The confirmed ORR was 31.7% in the NSCLC cohort and 10.0% in the UC cohort (all partial responses). Antitumor activity was observed irrespective of PD-L1 expression. In exploratory subgroups, ORRs were higher in patients with higher (≥median) CD8+ T cells in the tumor. ORRs were higher in patients with lower TMB (<median) in the NSCLC cohort and higher TMB (≥median) in the UC cohort. Treatment-related adverse events (TRAEs) occurred in 93.4% of patients, including grade ≥3 TRAEs in 55.7%. Avelumab exposures with 800 mg Q2W dosing were similar to those observed with 10 mg/kg Q2W dosing. CONCLUSIONS In previously treated patients with advanced/metastatic NSCLC, ORR appeared to be superior to anti-PD-L1 or anti-programmed cell death protein 1 monotherapy, irrespective of PD-L1 status, whereas in untreated, cisplatin-ineligible patients with advanced/metastatic UC, ORR was lower than expected, potentially limited by small patient numbers. TRIAL REGISTRATION Clinicaltrial.gov NCT03472560; https://clinicaltrials.gov/ct2/show/NCT03472560.
Collapse
Affiliation(s)
- G Galffy
- Department of Pulmonology, Pulmonology Hospital Törökbálint, Törökbálint, Hungary.
| | - I Lugowska
- Early Phase Clinical Trials Unit, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland; Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland
| | | | - B C Cho
- Division of Medical Oncology, Yonsei Cancer Center, Severance Hospital, Seoul
| | - M-J Ahn
- Department of Hematology & Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul
| | - J-Y Han
- Center for Lung Cancer, National Cancer Center, Goyang, Republic of Korea
| | - W-C Su
- Division of Hematology and Oncology, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan
| | - R J Hauke
- Department of Oncology, Nebraska Cancer Specialists, Omaha
| | - S H Dyar
- Department of Hematology & Oncology, Saint Francis Hospital Cancer Center, Greenville, USA
| | - D H Lee
- Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea
| | | | - D L Estelles
- Department of Oncology, Consorcio Hospitalario Provincial de Castellon, Castellon, Spain
| | - V R Holden
- Oncology Hematology Associates, Springfield, USA
| | - Y J Kim
- Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Republic of Korea
| | - V Vladimirov
- GBUZ of Stavropol Territory Pyatigorsk Inter-regional Oncology Dispensary, Pyatigorsk, Stavropol Territory, Russia
| | - Z Horvath
- Bács-Kiskun Megyei Kórház Onkoradiológiai Központ, Kecskemet, Hungary
| | - A Ghose
- Department of Medical Oncology/Hematology, Arizona Oncology Associates, Tempe
| | | | | | | | | | | | - M Laskov
- LLC University Clinic of Headache, Moscow, Russia
| |
Collapse
|
2
|
Paszt A, Simonka Z, Budai K, Horvath Z, Erdos M, Vas M, Ottlakan A, Nyari T, Szepes Z, Uhercsak G, Maraz A, Torday L, Tiszlavicz L, Olah J, Lazar G. Impact of neoadjuvant FLOT treatment of advanced gastric and gastroesophageal junction cancer following surgical therapy. Front Surg 2023; 10:1148984. [PMID: 37077865 PMCID: PMC10106678 DOI: 10.3389/fsurg.2023.1148984] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2023] [Accepted: 03/09/2023] [Indexed: 04/05/2023] Open
Abstract
IntroductionTherapeutic treatment for advanced-stage (T2–T4) gastroesophageal junction (GEJ) and gastric cancer involves neoadjuvant chemotherapy with subsequent surgical intervention.MethodNeoadjuvant oncological treatment for GEJ and gastric cancer previously consisted of the intravenous administration of epirubicin, cisplatin and fluorouracil (ECF) or epirubicin, cisplatin and capecitabine (ECX) combination (Group 1). The new protocol (FLOT, F: 5-FU, L: leucovorin, O: oxaliplatin, T: docetaxel), included patients with resectable GEJ and gastric cancer who had a clinical stage cT2 or higher nodal positive cN+ disease (Group 2). Between 31 December 2008 and 31 October 2022, the effect of different oncological protocols in terms of surgical outcomes in cases of T2–T4 tumours were retrospectively evaluated. Results of randomly assigned patients from the earlier ECF/ECX protocol (n = 36) (Group 1) and the new FLOT protocol (n = 52) (Group 2) were compared. Effect of different neoadjuvant therapies on tumour regression, types of possible side effects, type of surgery, and oncological radicality of surgical procedures were analysed.ResultsWhen comparing the two groups, we found that in case of the FLOT neoadjuvant chemotherapy (Group 2, n = 52), complete regression was achieved in 13.95% of patients, whereas in the case of ECF/ECX (Group 1, n = 36), complete regression occurred in only 9.10% of patients. Furthermore, in the FLOT group, the mean number of lymph nodes removed was slightly higher (24.69 vs. 20.13 in the ECF/ECX group). In terms of the safety resection margin (proximal), no significant difference was found between the two treatment groups. Nausea and vomiting were the most common side effects. The occurrence of diarrhea was significantly higher in the FLOT group (p = 0.006). Leukopenia and nausea occurred more commonly with the old protocol (Group 1). The rate of neutropenia was lower following FLOT treatment (p = 0.294), with the lack of grade II and III cases. Anaemia occured at a significantly higher rate (p = 0.036) after the ECF/ECX protocol.ConclusionsAs a result of the FLOT neoadjuvant oncological protocol for advanced gastro-esophageal junction and gastric cancer, the rate of complete tumour regression increased significantly. The rate of side effects was also appreciably lower following the FLOT protocol. These results strongly suggest a significant advantage of the FLOT neoadjuvant treatment used before surgery.
Collapse
Affiliation(s)
- Attila Paszt
- Department of Surgery, University of Szeged, Szeged, Hungary
- Correspondence: Attila Paszt
| | - Zsolt Simonka
- Department of Surgery, University of Szeged, Szeged, Hungary
| | - Krisztina Budai
- Department of Surgery, University of Szeged, Szeged, Hungary
| | - Zoltan Horvath
- Department of Surgery, University of Szeged, Szeged, Hungary
| | - Marton Erdos
- Department of Surgery, University of Szeged, Szeged, Hungary
| | - Marton Vas
- Department of Surgery, University of Szeged, Szeged, Hungary
| | - Aurel Ottlakan
- Department of Surgery, University of Szeged, Szeged, Hungary
| | - Tibor Nyari
- Department of Medical Physics and Informatics, University of Szeged, Szeged, Hungary
| | - Zoltan Szepes
- 1st Department of Internal Medicine, University of Szeged, Szeged, Hungary
| | | | - Aniko Maraz
- Department of Oncotherapy, University of Szeged, Szeged, Hungary
| | - Laszlo Torday
- Department of Oncotherapy, University of Szeged, Szeged, Hungary
| | | | - Judit Olah
- Department of Oncotherapy, University of Szeged, Szeged, Hungary
| | - Gyorgy Lazar
- Department of Surgery, University of Szeged, Szeged, Hungary
| |
Collapse
|
3
|
Racz I, Horvath A, Kranitz N, Kiss G, Regoczi H, Horvath Z. Artificial Intelligence-Based Colorectal Polyp Histology Prediction by Using Narrow-Band Image-Magnifying Colonoscopy. Clin Endosc 2021; 55:113-121. [PMID: 34551512 PMCID: PMC8831420 DOI: 10.5946/ce.2021.149] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/07/2021] [Accepted: 06/19/2021] [Indexed: 12/03/2022] Open
Abstract
Background/Aims We have been developing artificial intelligence based polyp histology prediction (AIPHP) method to classify Narrow Band Imaging (NBI) magnifying colonoscopy images to predict the hyperplastic or neoplastic histology of polyps. Our aim was to analyze the accuracy of AIPHP and narrow-band imaging international colorectal endoscopic (NICE) classification based histology predictions and also to compare the results of the two methods.
Methods We studied 373 colorectal polyp samples taken by polypectomy from 279 patients. The documented NBI still images were analyzed by the AIPHP method and by the NICE classification parallel. The AIPHP software was created by machine learning method. The software measures five geometrical and color features on the endoscopic image.
Results The accuracy of AIPHP was 86.6% (323/373) in total of polyps. We compared the AIPHP accuracy results for diminutive and non-diminutive polyps (82.1% vs. 92.2%; p=0.0032). The accuracy of the hyperplastic histology prediction was significantly better by NICE compared to AIPHP method both in the diminutive polyps (n=207) (95.2% vs. 82.1%) (p<0.001) and also in all evaluated polyps (n=373) (97.1% vs. 86.6%) (p<0.001)
Conclusions Our artificial intelligence based polyp histology prediction software could predict histology with high accuracy only in the large size polyp subgroup.
Collapse
Affiliation(s)
- Istvan Racz
- Department of Internal Medicine and Gastroenterology, Petz Aladar University Teaching Hospital, Gyor, Hungary
| | - Andras Horvath
- Department of Physics and Chemistry, Szechenyi Istvan University, Gyor, Hungary
| | - Noemi Kranitz
- Department of Pathology, Petz Aladar University Teaching Hospital, Gyor, Hungary
| | - Gyongyi Kiss
- Department of Internal Medicine and Gastroenterology, Petz Aladar University Teaching Hospital, Gyor, Hungary
| | - Henriett Regoczi
- Department of Internal Medicine and Gastroenterology, Petz Aladar University Teaching Hospital, Gyor, Hungary
| | - Zoltan Horvath
- Department of Mathematics and Informatics, Szechenyi Istvan University, Gyor, Hungary
| |
Collapse
|
4
|
Tard A, Arcella D, Boon P, Cascio C, Castle L, Gergelova P, Horvath Z, Leblanc JC, Lindtner O, Riolo F, Shah R. Dietary exposure assessment of sweeteners within their re-evaluation by the European Food Safety Authority (EFSA). Toxicol Lett 2021. [DOI: 10.1016/s0378-4274(21)00433-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
5
|
Vázquez-Fonseca L, Schaefer J, Navas-Enamorado I, Santos-Ocaña C, Hernández-Camacho JD, Guerra I, Cascajo MV, Sánchez-Cuesta A, Horvath Z, Siendones E, Jou C, Casado M, Gutiérrez P, Brea-Calvo G, López-Lluch G, Fernández-Ayala DJM, Cortés-Rodríguez AB, Rodríguez-Aguilera JC, Matté C, Ribes A, Prieto-Soler SY, Dominguez-Del-Toro E, Francesco AD, Aon MA, Bernier M, Salviati L, Artuch R, Cabo RD, Jackson S, Navas P. ADCK2 Haploinsufficiency Reduces Mitochondrial Lipid Oxidation and Causes Myopathy Associated with CoQ Deficiency. J Clin Med 2019; 8:jcm8091374. [PMID: 31480808 PMCID: PMC6780728 DOI: 10.3390/jcm8091374] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2019] [Revised: 08/28/2019] [Accepted: 08/29/2019] [Indexed: 01/27/2023] Open
Abstract
Fatty acids and glucose are the main bioenergetic substrates in mammals. Impairment of mitochondrial fatty acid oxidation causes mitochondrial myopathy leading to decreased physical performance. Here, we report that haploinsufficiency of ADCK2, a member of the aarF domain-containing mitochondrial protein kinase family, in human is associated with liver dysfunction and severe mitochondrial myopathy with lipid droplets in skeletal muscle. In order to better understand the etiology of this rare disorder, we generated a heterozygous Adck2 knockout mouse model to perform in vivo and cellular studies using integrated analysis of physiological and omics data (transcriptomics–metabolomics). The data showed that Adck2+/− mice exhibited impaired fatty acid oxidation, liver dysfunction, and mitochondrial myopathy in skeletal muscle resulting in lower physical performance. Significant decrease in Coenzyme Q (CoQ) biosynthesis was observed and supplementation with CoQ partially rescued the phenotype both in the human subject and mouse model. These results indicate that ADCK2 is involved in organismal fatty acid metabolism and in CoQ biosynthesis in skeletal muscle. We propose that patients with isolated myopathies and myopathies involving lipid accumulation be tested for possible ADCK2 defect as they are likely to be responsive to CoQ supplementation.
Collapse
Affiliation(s)
- Luis Vázquez-Fonseca
- Centro Andaluz de Biología del Desarrollo, Universidad Pablo de Olavide-CSIC-JA, 41013 Sevilla, Spain
- Clinical Genetics Unit, Department of Women and Children's Health, University of Padova, and IRP Città della Speranza, 35100 Padova, Italy
| | - Jochen Schaefer
- Department of Neurology, Carl Gustav Carus University Dresden, 01307 Dresden, Germany
| | - Ignacio Navas-Enamorado
- Centro Andaluz de Biología del Desarrollo, Universidad Pablo de Olavide-CSIC-JA, 41013 Sevilla, Spain
- Boston University School of Medicine, Boston, MA 02118, USA
- Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, 251 Bayview Boulevard, Suite 100, Baltimore, MD 20201, USA
| | - Carlos Santos-Ocaña
- Centro Andaluz de Biología del Desarrollo, Universidad Pablo de Olavide-CSIC-JA, 41013 Sevilla, Spain
- CIBERER, Instituto de Salud Carlos III, 28000 Madrid, Spain
| | - Juan D Hernández-Camacho
- Centro Andaluz de Biología del Desarrollo, Universidad Pablo de Olavide-CSIC-JA, 41013 Sevilla, Spain
- CIBERER, Instituto de Salud Carlos III, 28000 Madrid, Spain
| | - Ignacio Guerra
- Centro Andaluz de Biología del Desarrollo, Universidad Pablo de Olavide-CSIC-JA, 41013 Sevilla, Spain
| | - María V Cascajo
- Centro Andaluz de Biología del Desarrollo, Universidad Pablo de Olavide-CSIC-JA, 41013 Sevilla, Spain
- CIBERER, Instituto de Salud Carlos III, 28000 Madrid, Spain
| | - Ana Sánchez-Cuesta
- Centro Andaluz de Biología del Desarrollo, Universidad Pablo de Olavide-CSIC-JA, 41013 Sevilla, Spain
- CIBERER, Instituto de Salud Carlos III, 28000 Madrid, Spain
| | - Zoltan Horvath
- Department of Neurology, Carl Gustav Carus University Dresden, 01307 Dresden, Germany
| | - Emilio Siendones
- Centro Andaluz de Biología del Desarrollo, Universidad Pablo de Olavide-CSIC-JA, 41013 Sevilla, Spain
| | - Cristina Jou
- CIBERER, Instituto de Salud Carlos III, 28000 Madrid, Spain
- Clinical Chemistry and Pathology Departments, Institut de Recerca Sant Joan de Déu, 08000 Barcelona, Spain
| | - Mercedes Casado
- CIBERER, Instituto de Salud Carlos III, 28000 Madrid, Spain
- Clinical Chemistry and Pathology Departments, Institut de Recerca Sant Joan de Déu, 08000 Barcelona, Spain
| | - Purificación Gutiérrez
- Centro Andaluz de Biología del Desarrollo, Universidad Pablo de Olavide-CSIC-JA, 41013 Sevilla, Spain
| | - Gloria Brea-Calvo
- Centro Andaluz de Biología del Desarrollo, Universidad Pablo de Olavide-CSIC-JA, 41013 Sevilla, Spain
- CIBERER, Instituto de Salud Carlos III, 28000 Madrid, Spain
| | - Guillermo López-Lluch
- Centro Andaluz de Biología del Desarrollo, Universidad Pablo de Olavide-CSIC-JA, 41013 Sevilla, Spain
- CIBERER, Instituto de Salud Carlos III, 28000 Madrid, Spain
| | - Daniel J M Fernández-Ayala
- Centro Andaluz de Biología del Desarrollo, Universidad Pablo de Olavide-CSIC-JA, 41013 Sevilla, Spain
- CIBERER, Instituto de Salud Carlos III, 28000 Madrid, Spain
| | - Ana B Cortés-Rodríguez
- Centro Andaluz de Biología del Desarrollo, Universidad Pablo de Olavide-CSIC-JA, 41013 Sevilla, Spain
- CIBERER, Instituto de Salud Carlos III, 28000 Madrid, Spain
| | - Juan C Rodríguez-Aguilera
- Centro Andaluz de Biología del Desarrollo, Universidad Pablo de Olavide-CSIC-JA, 41013 Sevilla, Spain
- CIBERER, Instituto de Salud Carlos III, 28000 Madrid, Spain
| | - Cristiane Matté
- Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul. CEP 90035-003, Porto Alegre, RS, Brazil
| | - Antonia Ribes
- CIBERER, Instituto de Salud Carlos III, 28000 Madrid, Spain
- Secciód'Errors Congènits del Metabolisme-IBC, Servei de Bioquímica I Genètica Molecular, Hospital Clinic, 08000 Barcelona, Spain
| | | | | | - Andrea di Francesco
- Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, 251 Bayview Boulevard, Suite 100, Baltimore, MD 20201, USA
| | - Miguel A Aon
- Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, 251 Bayview Boulevard, Suite 100, Baltimore, MD 20201, USA
| | - Michel Bernier
- Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, 251 Bayview Boulevard, Suite 100, Baltimore, MD 20201, USA
| | - Leonardo Salviati
- Clinical Genetics Unit, Department of Women and Children's Health, University of Padova, and IRP Città della Speranza, 35100 Padova, Italy
| | - Rafael Artuch
- CIBERER, Instituto de Salud Carlos III, 28000 Madrid, Spain
- Clinical Chemistry and Pathology Departments, Institut de Recerca Sant Joan de Déu, 08000 Barcelona, Spain
| | - Rafael de Cabo
- Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, 251 Bayview Boulevard, Suite 100, Baltimore, MD 20201, USA
| | - Sandra Jackson
- Department of Neurology, Carl Gustav Carus University Dresden, 01307 Dresden, Germany
| | - Plácido Navas
- Centro Andaluz de Biología del Desarrollo, Universidad Pablo de Olavide-CSIC-JA, 41013 Sevilla, Spain.
- CIBERER, Instituto de Salud Carlos III, 28000 Madrid, Spain.
| |
Collapse
|
6
|
Horvath Z, Paszt A, Simonka Z, Latos M, Nagy J, Szirony D, Frittmann L, Kaizer L, Hamar S, Voros A, Ormandi K, Fejes Z, Lazar G. To do or not to do: axillary blockdissection after preoperative axillary ultrasound and aspiration cytology. Eur J Surg Oncol 2019. [DOI: 10.1016/j.ejso.2018.10.360] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
7
|
Boni V, Garcia-Corbacho J, Feliu J, Wydmanski J, Horvath Z, Bondarenko I, Irving B, Will M, de Vries E, Thistlethwaite F. The first-in-human, dose-finding PROCLAIM-CX-072 trial to assess the antitumor activity and tolerability of the probody therapeutic CX-072 as monotherapy and in combination with ipilimumab or vemurafenib in solid advanced tumors and lymphomas. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx367.056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
8
|
Vacirca JL, Agajanian R, Papai Z, Horvath Z, Makharadze R, Ibrahim EN, Choi MR, Song T, Tedesco KL, McGregor K, Schwartzberg LS. Abstract P5-11-09: Sustained efficacy of eflapegrastim in breast cancer patients in a phase 2, open-label, dose-ranging study. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p5-11-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Eflapegrastim is a distinct biologic that uses the innovative proprietary long-acting protein/peptide discovery technology (LAPSCOVERY™) and consists of a novel, modified recombinant human G-CSF conjugated to the Fc fragment of IgG4 via a polyethylene glycol linker. A Phase 2 study of 3 doses of eflapegrastim vs pegfilgrastim was conducted in breast cancer patients receiving docetaxel + cyclophosphamide (TC) chemotherapy.
Methods: This was an open-label, global, multicenter, dose-ranging study designed to compare the safety and efficacy of eflapegrastim relative to a fixed dose of pegfilgrastim as a concurrent active control. The study included 4 treatment arms: 3 dose levels of eflapegrastim (45 μg/kg, 135 μg/kg, and 270 μg/kg) vs pegfilgrastim (6 mg). The primary objective of the study was the Duration of Severe Neutropenia (DSN) during Cycle 1. The results for the primary objective, along with demographics and safety, were described in a previous presentation (SABCS 2015 P1-10-05). The secondary endpoints included DSN in Cycles 2-4, absolute neutrophil count (ANC) in Cycles 1-4, the overall incidences of febrile neutropenia (FN) and hospitalization rates.
Results: A total of 147 evaluable patients were enrolled. Patient and tumor characteristics were comparable across all 4 treatment arms. Median age was 59.0 years (range 32 to 77 years); most patients were <65 years (68%), Female (98%), and White (95%). The DSN for the 135 µg/kg and 270 µg/kg was non-inferior to pegfilgrastim during all cycles and the DSN for patients treated with 45 µg/kg was non-inferior during Cycles 2 and 3 (Table 1). The ANC was dose proportional across all 4 cycles. The incidence of FN and hospitalization rates was low in all arms and there were no significant differences between the Eflapegrastim and Pegfilgrastim Arms (Table 2).
Table 1. Duration of Severe Neutropenia in Cycles 2 to 4 of TC Chemotherapy by Treatment ArmDSN (Days)Eflapegrastim 45 μg/kg (N=39)Eflapegrastim 135 μg/kg (N=36)Eflapegrastim 270 μg/kg (N=36)Pegfilgrastim 6 mg (N=36)Cycle 2Difference with pegfilgrastim0.380.04-0.05NANon-Inferiority p-value0.001<0.001<0.001NACycle 3Difference with pegfilgrastim0.310.020.01NANon-Inferiority p-value0.002<0.001<0.001NACycle 4Difference with pegfilgrastim0.940.07-0.02NANon-Inferiority p-value0.781<0.001<0.001NADSN = Duration of Severe Neutropenia; NA = Not Applicable
Table 2. Incidence of Febrile Neutropenia and Hospitalizations Eflapegrastim 45 μg/kg (N=39)Eflapegrastim 135 μg/kg (N=36)Eflapegrastim 270 μg/kg (N=36)Pegfilgrastim 6 mg (N=36)Febrile NeutropeniaIncidence (%)3 (7.7%)1 (2.8%)1 (2.8%)2 (5.6%)Difference with Pegfilgrastim2.1 %-2.8%-2.8%NAp-value1.0001.0001.000NAHospitalizationsIncidence (%)3 (7.7%)3 (8.3%)1 (2.8%)5 (13.9%)Difference with Pegfilgrastim-6.2%-5.6%-11.1%NAp-value0.4690.7100.199NA
Conclusions: In breast cancer patients treated with TC, the non-inferiority of DSN of 135 µg/kg and 270 µg/kg eflapegrastim, compared to pegfilgrastim in Cycle 1, was sustained through Cycles 2-4 and the ANC profiles were comparable in Cycles 1-4. In addition, the overall incidence of FN and hospitalizations was comparable between the eflapegrastim arms and the pegfilgrastim arm.
Citation Format: Vacirca JL, Agajanian R, Papai Z, Horvath Z, Makharadze R, Ibrahim EN, Choi MR, Song T, Tedesco KL, McGregor K, Schwartzberg LS. Sustained efficacy of eflapegrastim in breast cancer patients in a phase 2, open-label, dose-ranging study [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-11-09.
Collapse
Affiliation(s)
- JL Vacirca
- North Shore Hematology/Oncology, East Setauket, NY; The Oncology Institute of Hope and Innovation, Downey, CA; State Health Center, Budapest, Hungary; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; Samaritan Hematology and Oncology Associates, Corvallis, OR; West Cancer Center, Memphis, TN
| | - R Agajanian
- North Shore Hematology/Oncology, East Setauket, NY; The Oncology Institute of Hope and Innovation, Downey, CA; State Health Center, Budapest, Hungary; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; Samaritan Hematology and Oncology Associates, Corvallis, OR; West Cancer Center, Memphis, TN
| | - Z Papai
- North Shore Hematology/Oncology, East Setauket, NY; The Oncology Institute of Hope and Innovation, Downey, CA; State Health Center, Budapest, Hungary; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; Samaritan Hematology and Oncology Associates, Corvallis, OR; West Cancer Center, Memphis, TN
| | - Z Horvath
- North Shore Hematology/Oncology, East Setauket, NY; The Oncology Institute of Hope and Innovation, Downey, CA; State Health Center, Budapest, Hungary; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; Samaritan Hematology and Oncology Associates, Corvallis, OR; West Cancer Center, Memphis, TN
| | - R Makharadze
- North Shore Hematology/Oncology, East Setauket, NY; The Oncology Institute of Hope and Innovation, Downey, CA; State Health Center, Budapest, Hungary; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; Samaritan Hematology and Oncology Associates, Corvallis, OR; West Cancer Center, Memphis, TN
| | - EN Ibrahim
- North Shore Hematology/Oncology, East Setauket, NY; The Oncology Institute of Hope and Innovation, Downey, CA; State Health Center, Budapest, Hungary; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; Samaritan Hematology and Oncology Associates, Corvallis, OR; West Cancer Center, Memphis, TN
| | - MR Choi
- North Shore Hematology/Oncology, East Setauket, NY; The Oncology Institute of Hope and Innovation, Downey, CA; State Health Center, Budapest, Hungary; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; Samaritan Hematology and Oncology Associates, Corvallis, OR; West Cancer Center, Memphis, TN
| | - T Song
- North Shore Hematology/Oncology, East Setauket, NY; The Oncology Institute of Hope and Innovation, Downey, CA; State Health Center, Budapest, Hungary; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; Samaritan Hematology and Oncology Associates, Corvallis, OR; West Cancer Center, Memphis, TN
| | - KL Tedesco
- North Shore Hematology/Oncology, East Setauket, NY; The Oncology Institute of Hope and Innovation, Downey, CA; State Health Center, Budapest, Hungary; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; Samaritan Hematology and Oncology Associates, Corvallis, OR; West Cancer Center, Memphis, TN
| | - K McGregor
- North Shore Hematology/Oncology, East Setauket, NY; The Oncology Institute of Hope and Innovation, Downey, CA; State Health Center, Budapest, Hungary; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; Samaritan Hematology and Oncology Associates, Corvallis, OR; West Cancer Center, Memphis, TN
| | - LS Schwartzberg
- North Shore Hematology/Oncology, East Setauket, NY; The Oncology Institute of Hope and Innovation, Downey, CA; State Health Center, Budapest, Hungary; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; Samaritan Hematology and Oncology Associates, Corvallis, OR; West Cancer Center, Memphis, TN
| |
Collapse
|
9
|
Vacirca JL, Papai Z, Horvath Z, Makharadze R, Reddy G, Song T, Koli P, Schwartzberg LS. Abstract P5-11-07: Pharmacokinetics of eflapegrastim in a phase 2 open-label dose-ranging study in breast cancer patients receiving TC regimen. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p5-11-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Eflapegrastim (SPI-2012/HM10460A) is a novel, long acting recombinant human granulocyte colony-stimulating factor (rhG-CSF). Eflapegrastim consists of an rhG-CSF conjugated to the recombinant E coli derived Fc fragment of IgG4 via a polyethylene glycol linker. Eflapegrastim is in clinical development for the treatment of chemotherapy induced neutropenia in cancer patients.
Methods: Pharmacokinetics (PK) of eflapegrastim was investigated in an open label, dose-ranging Phase 2 study in breast cancer patients receiving docetaxel + cyclophosphamide (TC) chemotherapy. The study consisted of 4 arms. Patients in Arms 1 through 3 received subcutaneous doses of 45, 135, or 270 µg /kg of eflapegrastim and patients in Arm 4 received 6 mg pegfilgrastim (Neulasta®) on Day 2 of each 21-day chemotherapy cycle. Serum samples were collected from a subset of eflapegrastim patients at pre-specified time-points and analyzed for eflapegrastim by a validated enzyme-linked immunosorption assay (ELISA). Pharmacokinetic analyses were conducted on serum concentration-time profiles after dosing in Cycle 1. The serum concentrations for samples collected in Cycle 3 were compared with the corresponding concentrations in Cycle 1. Pharmacokinetic analyses were not conducted for pegfilgrastim patients.
Results: The PK profile of eflapegrastim was investigated in 11 patients, including 3 patients in the 45 µg/kg treatment arm, 4 patients in the 135 µg/kg treatment arm, and 4 patients in the 270 µg/kg treatment arm. Following single eflapegrastim doses of 45, 135, or 270 µg/kg, peak serum concentrations increased in a dose proportional manner. The summary of pharmacokinetics of eflapegrastim is presented in the Table below.
Pharmacokinetic Parameters of Eflapegrastim in Patients Following Single Subcutaneous Doses in Cycle 1ParameterEflapegrastim 45 μg/kg/Eflapegrastim 135μg/kgEflapegrastim 270 μg/kgCmax, ng/mLN = 3; Mean = 7.00; SD = 6.08N = 4; Mean = 247; SD = 276N =3; Mean = 299; SD = 329Tmax, haN =2; Mean = 58.7; SD = 46.9 - 70.5N = 4; Mean =9.00; SD = 8 - 48.1N = 3; Mean = 24.00; SD = 24 - 24.1AUC0-312, ng•hr/mLN = 0; Mean = NC; SD = NCN = 2; Mean = 16000; SD = 5850N = 3; Mean = 22900; SD = 25100t1/2, hbN = 0; Mean = NC; SD = NCN = 2; Mean = 81.0; SD = 88.4N = 1; Mean = 31.5; SD = NCAUC = area under the concentration-time curve; Cmax = maximum serum concentration; h = hour; NC = not calculated; SD = standard deviation; t1/2 = half-life; Tmax = time to maximum serum concentration; a) Expressed as median and range; b) Expressed as harmonic mean and pseudo SD
The maximum serum concentrations of eflapegrastim in Cycle 3 increased with the dose of eflapegrastim. The serum concentrations of eflapegrastim in Cycle 3 were generally lower than those in Cycle 1, but the profile was similar to Cycle 1.
Conclusions: The Cmax and AUC(0-312) of eflapegrastim increased in a dose proportional manner following subcutaneous administration. The half-life of eflapegrastim ranged from 31.5 to 81.0 hours, which is consistent with the half-life of other long-acting myeloid growth factors.
Citation Format: Vacirca JL, Papai Z, Horvath Z, Makharadze R, Reddy G, Song T, Koli P, Schwartzberg LS. Pharmacokinetics of eflapegrastim in a phase 2 open-label dose-ranging study in breast cancer patients receiving TC regimen [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-11-07.
Collapse
Affiliation(s)
- JL Vacirca
- North Shore Hematology/Oncology Associates, East Setauket, NY; State Health Center, Budapest, Hungary; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; West Cancer Center, Memphis, TN
| | - Z Papai
- North Shore Hematology/Oncology Associates, East Setauket, NY; State Health Center, Budapest, Hungary; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; West Cancer Center, Memphis, TN
| | - Z Horvath
- North Shore Hematology/Oncology Associates, East Setauket, NY; State Health Center, Budapest, Hungary; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; West Cancer Center, Memphis, TN
| | - R Makharadze
- North Shore Hematology/Oncology Associates, East Setauket, NY; State Health Center, Budapest, Hungary; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; West Cancer Center, Memphis, TN
| | - G Reddy
- North Shore Hematology/Oncology Associates, East Setauket, NY; State Health Center, Budapest, Hungary; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; West Cancer Center, Memphis, TN
| | - T Song
- North Shore Hematology/Oncology Associates, East Setauket, NY; State Health Center, Budapest, Hungary; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; West Cancer Center, Memphis, TN
| | - P Koli
- North Shore Hematology/Oncology Associates, East Setauket, NY; State Health Center, Budapest, Hungary; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; West Cancer Center, Memphis, TN
| | - LS Schwartzberg
- North Shore Hematology/Oncology Associates, East Setauket, NY; State Health Center, Budapest, Hungary; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; West Cancer Center, Memphis, TN
| |
Collapse
|
10
|
Vacirca JL, Papai Z, Agajanian R, Horvath Z, Makharadze R, Ibrahim E, Koli P, Reddy G, Tedesco KL, McGregor K, Schwartzberg LS. Abstract P5-11-08: Immunogenicity of eflapegrastim in a phase 2 open-label dose-ranging study of eflapegrastim in breast cancer patients receiving TC regimen. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p5-11-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Eflapegrastim (SPI-2012/HM10460A) is a novel, long-acting recombinant human granulocyte colony-stimulating factor (rhG-CSF). Eflapegrastim consists of an rhG-CSF conjugated to a recombinant E. coli derived Fc fragment of IgG4 via a polyethylene glycol linker. Eflapegrastim is in clinical development for the treatment of chemotherapy induced neutropenia in cancer patients.
Methods: Immunogenicity of eflapegrastim was investigated in an open label, dose-ranging Phase 2 study in breast cancer patients receiving docetaxel + cyclophosphamide (TC) chemotherapy. The study consisted of 4 arms. Patients in Arms 1 through 3 received subcutaneous doses of 45, 135, or 270 µg/kg eflapegrastim and Arm 4 received 6 mg pegfilgrastim (Neulasta®) on Day 2 of each 21-day chemotherapy cycle. Blood samples for immunogenicity analysis were collected before the start of each chemotherapy cycle (Day 1) and at the End-of-Study Visit. Samples were tested in a screening assay for Anti-Drug Antibodies (ADA) to eflapegrastim by a validated enzyme linked immunosorption assay (ELISA). Positive samples from the screening assay were further tested in a confirmatory assay for antibodies binding to eflapegrastim or G-CSF. Samples found positive in the confirmatory assay were further tested in a validated cell based neutralizing antibody assay.
Results: Serum samples from 143 patients in the study were tested for ADA to eflapegrastim and G-CSF. Preexisting antibodies binding to eflapegrastim or G-CSF were detected in 9 out of 143 (6.3%) patients. One out of the 27 patients (3.7%) in the Pegfilgrastim Arm who was negative prior to dosing was positive for ADA in the G-CSF confirmatory assay. Two out of 100 patients (2.0%) treated with eflapegrastim, who were negative prior to dosing, demonstrated treatment-induced formation of ADA in the G-CSF confirmatory assay. However, the responses in these patients were transient (ie, not consistently positive at all the sampling times) and the assay response values were low and only slightly above the plate-specific cut points. None of the patients tested were positive for G-CSF neutralizing antibodies. A formal assessment of the impact of serum ADA on the PK of eflapegrastim was not performed since PK was examined in only a limited number of patients and all of those patients were negative for ADA both at study initiation and post-dose.
Conclusion: No neutralizing antibodies against eflapegrastim or G-CSF were detected in patients administered eflapegrastim in this study.
Citation Format: Vacirca JL, Papai Z, Agajanian R, Horvath Z, Makharadze R, Ibrahim E, Koli P, Reddy G, Tedesco KL, McGregor K, Schwartzberg LS. Immunogenicity of eflapegrastim in a phase 2 open-label dose-ranging study of eflapegrastim in breast cancer patients receiving TC regimen [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-11-08.
Collapse
Affiliation(s)
- JL Vacirca
- North Shore Hematology/Oncology Associates, East Setauket, NY; State Health Center, Budapest, Hungary; The Oncology Institute of Hope and Innovation, Downey, CA; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; Samaritan Hematology and Oncology Associates, Corvallis, OR; West Cancer Center, Memphis, TN
| | - Z Papai
- North Shore Hematology/Oncology Associates, East Setauket, NY; State Health Center, Budapest, Hungary; The Oncology Institute of Hope and Innovation, Downey, CA; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; Samaritan Hematology and Oncology Associates, Corvallis, OR; West Cancer Center, Memphis, TN
| | - R Agajanian
- North Shore Hematology/Oncology Associates, East Setauket, NY; State Health Center, Budapest, Hungary; The Oncology Institute of Hope and Innovation, Downey, CA; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; Samaritan Hematology and Oncology Associates, Corvallis, OR; West Cancer Center, Memphis, TN
| | - Z Horvath
- North Shore Hematology/Oncology Associates, East Setauket, NY; State Health Center, Budapest, Hungary; The Oncology Institute of Hope and Innovation, Downey, CA; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; Samaritan Hematology and Oncology Associates, Corvallis, OR; West Cancer Center, Memphis, TN
| | - R Makharadze
- North Shore Hematology/Oncology Associates, East Setauket, NY; State Health Center, Budapest, Hungary; The Oncology Institute of Hope and Innovation, Downey, CA; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; Samaritan Hematology and Oncology Associates, Corvallis, OR; West Cancer Center, Memphis, TN
| | - E Ibrahim
- North Shore Hematology/Oncology Associates, East Setauket, NY; State Health Center, Budapest, Hungary; The Oncology Institute of Hope and Innovation, Downey, CA; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; Samaritan Hematology and Oncology Associates, Corvallis, OR; West Cancer Center, Memphis, TN
| | - P Koli
- North Shore Hematology/Oncology Associates, East Setauket, NY; State Health Center, Budapest, Hungary; The Oncology Institute of Hope and Innovation, Downey, CA; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; Samaritan Hematology and Oncology Associates, Corvallis, OR; West Cancer Center, Memphis, TN
| | - G Reddy
- North Shore Hematology/Oncology Associates, East Setauket, NY; State Health Center, Budapest, Hungary; The Oncology Institute of Hope and Innovation, Downey, CA; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; Samaritan Hematology and Oncology Associates, Corvallis, OR; West Cancer Center, Memphis, TN
| | - KL Tedesco
- North Shore Hematology/Oncology Associates, East Setauket, NY; State Health Center, Budapest, Hungary; The Oncology Institute of Hope and Innovation, Downey, CA; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; Samaritan Hematology and Oncology Associates, Corvallis, OR; West Cancer Center, Memphis, TN
| | - K McGregor
- North Shore Hematology/Oncology Associates, East Setauket, NY; State Health Center, Budapest, Hungary; The Oncology Institute of Hope and Innovation, Downey, CA; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; Samaritan Hematology and Oncology Associates, Corvallis, OR; West Cancer Center, Memphis, TN
| | - LS Schwartzberg
- North Shore Hematology/Oncology Associates, East Setauket, NY; State Health Center, Budapest, Hungary; The Oncology Institute of Hope and Innovation, Downey, CA; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Beaver Medical Group, Highland, CA; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; Samaritan Hematology and Oncology Associates, Corvallis, OR; West Cancer Center, Memphis, TN
| |
Collapse
|
11
|
Horvath Z, Paszt A, Simonka Z, Nagyszegi D, Kaizer L, Hamar S, Csorgo E, Lazar G. 45. Is intraoperative imprint cytology indicated in the surgical treatment of early breast cancers? Eur J Surg Oncol 2016. [DOI: 10.1016/j.ejso.2016.06.051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
12
|
Vacirca JL, Chan A, Mezei K, Adoo CS, Papai Z, McGregor K, Okera M, Horvath Z, Landherr L, Hanslik J, Hager SJ, Ibrahim EN, Ghazal H, Rostom M, Bhat G, Choi MR, Allen LF, Tedesco KL, Agajanian R, Lang I. Abstract P1-10-05: Randomized phase 2, open-label, dose-ranging study of a novel, long-acting G-CSF (SPI-2012) or pegfilgrastim for the management of neutropenia in patients with breast cancer (BC) treated with (Neo) adjuvant chemotherapy with docetaxel + cyclophosphamide (TC). Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p1-10-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: SPI-2012 is a distinct biologic that uses the innovative proprietary long-acting protein/peptide discovery technology (LAPSCOVERY™) to enhance the activity of G-CSF. SPI-2012 consists of a novel, modified recombinant human G-CSF conjugated to the Fc fragment of IgG4 via a polyethylene glycol linker to produce a new, more potent, longer-acting G-CSF with a potentially unique distribution to areas rich in Fc receptors. To assess the effect of SPI-2012 in supporting patients with breast cancer receiving myelosuppressive chemotherapy with TC, we conducted a randomized Phase 2 study of 3 SPI-2012 doses versus pegfilgrastim.
Methods: This was an open-label, global, multicenter, dose-ranging study designed to compare the safety and efficacy of SPI-2012 relative to a fixed, standard dose of pegfilgrastim as a concurrent active control. The study included 4 treatment arms: 3 dose levels of SPI-2012 (45 μg/kg, 135 μg/kg, and 270 μg/kg) vs pegfilgrastim (6 mg,). The primary objective of the study was the Duration of Severe Neutropenia (DSN) during Cycle 1 in patients with BC who received adjuvant or neoadjuvant TC chemotherapy.
Results: A total of 147 evaluable patients were enrolled. Patient and tumor characteristics were comparable across all 4 treatment arms. Mean age was 58.2 years (range 32 to 77 years); most patients were <65 years (68%), female (98%) and white (95%). The study met its primary endpoint with DSN in patients treated in the 135 µg/kg and 270 µg/kg SPI-2012 treatment arms in Cycle 1 showing non-inferiority to the DSN in patients treated with pegfilgrastim (p=0.002 and p<0.001, respectively). In addition, superiority was demonstrated in patients treated with 270 µg/kg SPI-2012 compared to pegfilgrastim (p=0.023). Non-inferiority in DSN was also observed in Cycles 2 to 4 in both the 135 µg/kg and 270 µg/kg SPI-2012 treatment arms compared to pegfilgrastim.
Duration of Severe Neutropenia in Cycle 1 of TC chemotherapy by Treatment Arm 45 μg/kg SPI-2012 (N=39) 135 μg/kg SPI-2012 (N=36) 270 μg/kg SPI-2012 (N=36)Pegfilgrastim (N=36)DSN Mean (SD)(days)1.03 (1.5)0.44 (1.3)0.03 (0.2)0.31 (0.8)Difference with pegfilgrastim0.720.14-0.28NANon-inferiority p-value0.2960.002<0.001NASuperiority p-value0.0060.5280.023NASD=Standard Deviation; NA=Not Applicable
The common treatment-emergent adverse events observed in ≥20% of patients were similar across all 4 study arms with similar or lower incidence in the SPI-2012 treatment arms, and included fatigue, nausea, alopecia, diarrhea, and bone pain.
Conclusions: All doses of SPI-2012 administered in this Phase 2 study were well tolerated, and no new or significant dose-related toxicities were observed. Most reported adverse events were mild and similar to those previously reported in clinical trials with filgrastim and pegfilgrastim in patients receiving myelosuppressive chemotherapy. In Cycle 1, the 135 µg/kg dose of SPI-2012 was non-inferior compared to pegfilgrastim, and the 270 µg/kg dose was superior in terms of DSN. Additional efficacy and safety data for SPI-2012 will be collected in planned Phase 3 clinical trials.
Citation Format: Vacirca JL, Chan A, Mezei K, Adoo CS, Papai Z, McGregor K, Okera M, Horvath Z, Landherr L, Hanslik J, Hager SJ, Ibrahim EN, Ghazal H, Rostom M, Bhat G, Choi MR, Allen LF, Tedesco KL, Agajanian R, Lang I. Randomized phase 2, open-label, dose-ranging study of a novel, long-acting G-CSF (SPI-2012) or pegfilgrastim for the management of neutropenia in patients with breast cancer (BC) treated with (Neo) adjuvant chemotherapy with docetaxel + cyclophosphamide (TC). [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-10-05.
Collapse
Affiliation(s)
- JL Vacirca
- North Shore Hematology/Oncology, East Setaukut, NY; Breast Cancer Research Centre WA and Curtin University, Perth, Western Australia, Australia; Szabolcs Szatmar Bereg County Hospital and University Teaching Hospital, Nyíregyháza, Hungary; Arizona Center for Cancer Care, Glendale, AZ; State Health Center, Budapest, Hungary; Samaritan Hematology and Oncology Associates, Corvalis, OR; Adelaide Cancer Centre, Kurralta Park, South Australia, Australia; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Uzsoki Hospital, Center of Oncoradiology, Budapest, Hungary; Szpital Rejonowy Dzienny Oddzial Chemioterapii, Racibórz, Poland; California Cancer Associates for Research and Excellence, Fresno, CA; Beaver Medical Group, Highland, CA; Hazard ARH Regional Medical Center, Hazard, KY; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation,
| | - A Chan
- North Shore Hematology/Oncology, East Setaukut, NY; Breast Cancer Research Centre WA and Curtin University, Perth, Western Australia, Australia; Szabolcs Szatmar Bereg County Hospital and University Teaching Hospital, Nyíregyháza, Hungary; Arizona Center for Cancer Care, Glendale, AZ; State Health Center, Budapest, Hungary; Samaritan Hematology and Oncology Associates, Corvalis, OR; Adelaide Cancer Centre, Kurralta Park, South Australia, Australia; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Uzsoki Hospital, Center of Oncoradiology, Budapest, Hungary; Szpital Rejonowy Dzienny Oddzial Chemioterapii, Racibórz, Poland; California Cancer Associates for Research and Excellence, Fresno, CA; Beaver Medical Group, Highland, CA; Hazard ARH Regional Medical Center, Hazard, KY; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation,
| | - K Mezei
- North Shore Hematology/Oncology, East Setaukut, NY; Breast Cancer Research Centre WA and Curtin University, Perth, Western Australia, Australia; Szabolcs Szatmar Bereg County Hospital and University Teaching Hospital, Nyíregyháza, Hungary; Arizona Center for Cancer Care, Glendale, AZ; State Health Center, Budapest, Hungary; Samaritan Hematology and Oncology Associates, Corvalis, OR; Adelaide Cancer Centre, Kurralta Park, South Australia, Australia; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Uzsoki Hospital, Center of Oncoradiology, Budapest, Hungary; Szpital Rejonowy Dzienny Oddzial Chemioterapii, Racibórz, Poland; California Cancer Associates for Research and Excellence, Fresno, CA; Beaver Medical Group, Highland, CA; Hazard ARH Regional Medical Center, Hazard, KY; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation,
| | - CS Adoo
- North Shore Hematology/Oncology, East Setaukut, NY; Breast Cancer Research Centre WA and Curtin University, Perth, Western Australia, Australia; Szabolcs Szatmar Bereg County Hospital and University Teaching Hospital, Nyíregyháza, Hungary; Arizona Center for Cancer Care, Glendale, AZ; State Health Center, Budapest, Hungary; Samaritan Hematology and Oncology Associates, Corvalis, OR; Adelaide Cancer Centre, Kurralta Park, South Australia, Australia; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Uzsoki Hospital, Center of Oncoradiology, Budapest, Hungary; Szpital Rejonowy Dzienny Oddzial Chemioterapii, Racibórz, Poland; California Cancer Associates for Research and Excellence, Fresno, CA; Beaver Medical Group, Highland, CA; Hazard ARH Regional Medical Center, Hazard, KY; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation,
| | - Z Papai
- North Shore Hematology/Oncology, East Setaukut, NY; Breast Cancer Research Centre WA and Curtin University, Perth, Western Australia, Australia; Szabolcs Szatmar Bereg County Hospital and University Teaching Hospital, Nyíregyháza, Hungary; Arizona Center for Cancer Care, Glendale, AZ; State Health Center, Budapest, Hungary; Samaritan Hematology and Oncology Associates, Corvalis, OR; Adelaide Cancer Centre, Kurralta Park, South Australia, Australia; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Uzsoki Hospital, Center of Oncoradiology, Budapest, Hungary; Szpital Rejonowy Dzienny Oddzial Chemioterapii, Racibórz, Poland; California Cancer Associates for Research and Excellence, Fresno, CA; Beaver Medical Group, Highland, CA; Hazard ARH Regional Medical Center, Hazard, KY; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation,
| | - K McGregor
- North Shore Hematology/Oncology, East Setaukut, NY; Breast Cancer Research Centre WA and Curtin University, Perth, Western Australia, Australia; Szabolcs Szatmar Bereg County Hospital and University Teaching Hospital, Nyíregyháza, Hungary; Arizona Center for Cancer Care, Glendale, AZ; State Health Center, Budapest, Hungary; Samaritan Hematology and Oncology Associates, Corvalis, OR; Adelaide Cancer Centre, Kurralta Park, South Australia, Australia; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Uzsoki Hospital, Center of Oncoradiology, Budapest, Hungary; Szpital Rejonowy Dzienny Oddzial Chemioterapii, Racibórz, Poland; California Cancer Associates for Research and Excellence, Fresno, CA; Beaver Medical Group, Highland, CA; Hazard ARH Regional Medical Center, Hazard, KY; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation,
| | - M Okera
- North Shore Hematology/Oncology, East Setaukut, NY; Breast Cancer Research Centre WA and Curtin University, Perth, Western Australia, Australia; Szabolcs Szatmar Bereg County Hospital and University Teaching Hospital, Nyíregyháza, Hungary; Arizona Center for Cancer Care, Glendale, AZ; State Health Center, Budapest, Hungary; Samaritan Hematology and Oncology Associates, Corvalis, OR; Adelaide Cancer Centre, Kurralta Park, South Australia, Australia; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Uzsoki Hospital, Center of Oncoradiology, Budapest, Hungary; Szpital Rejonowy Dzienny Oddzial Chemioterapii, Racibórz, Poland; California Cancer Associates for Research and Excellence, Fresno, CA; Beaver Medical Group, Highland, CA; Hazard ARH Regional Medical Center, Hazard, KY; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation,
| | - Z Horvath
- North Shore Hematology/Oncology, East Setaukut, NY; Breast Cancer Research Centre WA and Curtin University, Perth, Western Australia, Australia; Szabolcs Szatmar Bereg County Hospital and University Teaching Hospital, Nyíregyháza, Hungary; Arizona Center for Cancer Care, Glendale, AZ; State Health Center, Budapest, Hungary; Samaritan Hematology and Oncology Associates, Corvalis, OR; Adelaide Cancer Centre, Kurralta Park, South Australia, Australia; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Uzsoki Hospital, Center of Oncoradiology, Budapest, Hungary; Szpital Rejonowy Dzienny Oddzial Chemioterapii, Racibórz, Poland; California Cancer Associates for Research and Excellence, Fresno, CA; Beaver Medical Group, Highland, CA; Hazard ARH Regional Medical Center, Hazard, KY; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation,
| | - L Landherr
- North Shore Hematology/Oncology, East Setaukut, NY; Breast Cancer Research Centre WA and Curtin University, Perth, Western Australia, Australia; Szabolcs Szatmar Bereg County Hospital and University Teaching Hospital, Nyíregyháza, Hungary; Arizona Center for Cancer Care, Glendale, AZ; State Health Center, Budapest, Hungary; Samaritan Hematology and Oncology Associates, Corvalis, OR; Adelaide Cancer Centre, Kurralta Park, South Australia, Australia; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Uzsoki Hospital, Center of Oncoradiology, Budapest, Hungary; Szpital Rejonowy Dzienny Oddzial Chemioterapii, Racibórz, Poland; California Cancer Associates for Research and Excellence, Fresno, CA; Beaver Medical Group, Highland, CA; Hazard ARH Regional Medical Center, Hazard, KY; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation,
| | - J Hanslik
- North Shore Hematology/Oncology, East Setaukut, NY; Breast Cancer Research Centre WA and Curtin University, Perth, Western Australia, Australia; Szabolcs Szatmar Bereg County Hospital and University Teaching Hospital, Nyíregyháza, Hungary; Arizona Center for Cancer Care, Glendale, AZ; State Health Center, Budapest, Hungary; Samaritan Hematology and Oncology Associates, Corvalis, OR; Adelaide Cancer Centre, Kurralta Park, South Australia, Australia; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Uzsoki Hospital, Center of Oncoradiology, Budapest, Hungary; Szpital Rejonowy Dzienny Oddzial Chemioterapii, Racibórz, Poland; California Cancer Associates for Research and Excellence, Fresno, CA; Beaver Medical Group, Highland, CA; Hazard ARH Regional Medical Center, Hazard, KY; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation,
| | - SJ Hager
- North Shore Hematology/Oncology, East Setaukut, NY; Breast Cancer Research Centre WA and Curtin University, Perth, Western Australia, Australia; Szabolcs Szatmar Bereg County Hospital and University Teaching Hospital, Nyíregyháza, Hungary; Arizona Center for Cancer Care, Glendale, AZ; State Health Center, Budapest, Hungary; Samaritan Hematology and Oncology Associates, Corvalis, OR; Adelaide Cancer Centre, Kurralta Park, South Australia, Australia; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Uzsoki Hospital, Center of Oncoradiology, Budapest, Hungary; Szpital Rejonowy Dzienny Oddzial Chemioterapii, Racibórz, Poland; California Cancer Associates for Research and Excellence, Fresno, CA; Beaver Medical Group, Highland, CA; Hazard ARH Regional Medical Center, Hazard, KY; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation,
| | - EN Ibrahim
- North Shore Hematology/Oncology, East Setaukut, NY; Breast Cancer Research Centre WA and Curtin University, Perth, Western Australia, Australia; Szabolcs Szatmar Bereg County Hospital and University Teaching Hospital, Nyíregyháza, Hungary; Arizona Center for Cancer Care, Glendale, AZ; State Health Center, Budapest, Hungary; Samaritan Hematology and Oncology Associates, Corvalis, OR; Adelaide Cancer Centre, Kurralta Park, South Australia, Australia; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Uzsoki Hospital, Center of Oncoradiology, Budapest, Hungary; Szpital Rejonowy Dzienny Oddzial Chemioterapii, Racibórz, Poland; California Cancer Associates for Research and Excellence, Fresno, CA; Beaver Medical Group, Highland, CA; Hazard ARH Regional Medical Center, Hazard, KY; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation,
| | - H Ghazal
- North Shore Hematology/Oncology, East Setaukut, NY; Breast Cancer Research Centre WA and Curtin University, Perth, Western Australia, Australia; Szabolcs Szatmar Bereg County Hospital and University Teaching Hospital, Nyíregyháza, Hungary; Arizona Center for Cancer Care, Glendale, AZ; State Health Center, Budapest, Hungary; Samaritan Hematology and Oncology Associates, Corvalis, OR; Adelaide Cancer Centre, Kurralta Park, South Australia, Australia; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Uzsoki Hospital, Center of Oncoradiology, Budapest, Hungary; Szpital Rejonowy Dzienny Oddzial Chemioterapii, Racibórz, Poland; California Cancer Associates for Research and Excellence, Fresno, CA; Beaver Medical Group, Highland, CA; Hazard ARH Regional Medical Center, Hazard, KY; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation,
| | - M Rostom
- North Shore Hematology/Oncology, East Setaukut, NY; Breast Cancer Research Centre WA and Curtin University, Perth, Western Australia, Australia; Szabolcs Szatmar Bereg County Hospital and University Teaching Hospital, Nyíregyháza, Hungary; Arizona Center for Cancer Care, Glendale, AZ; State Health Center, Budapest, Hungary; Samaritan Hematology and Oncology Associates, Corvalis, OR; Adelaide Cancer Centre, Kurralta Park, South Australia, Australia; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Uzsoki Hospital, Center of Oncoradiology, Budapest, Hungary; Szpital Rejonowy Dzienny Oddzial Chemioterapii, Racibórz, Poland; California Cancer Associates for Research and Excellence, Fresno, CA; Beaver Medical Group, Highland, CA; Hazard ARH Regional Medical Center, Hazard, KY; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation,
| | - G Bhat
- North Shore Hematology/Oncology, East Setaukut, NY; Breast Cancer Research Centre WA and Curtin University, Perth, Western Australia, Australia; Szabolcs Szatmar Bereg County Hospital and University Teaching Hospital, Nyíregyháza, Hungary; Arizona Center for Cancer Care, Glendale, AZ; State Health Center, Budapest, Hungary; Samaritan Hematology and Oncology Associates, Corvalis, OR; Adelaide Cancer Centre, Kurralta Park, South Australia, Australia; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Uzsoki Hospital, Center of Oncoradiology, Budapest, Hungary; Szpital Rejonowy Dzienny Oddzial Chemioterapii, Racibórz, Poland; California Cancer Associates for Research and Excellence, Fresno, CA; Beaver Medical Group, Highland, CA; Hazard ARH Regional Medical Center, Hazard, KY; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation,
| | - MR Choi
- North Shore Hematology/Oncology, East Setaukut, NY; Breast Cancer Research Centre WA and Curtin University, Perth, Western Australia, Australia; Szabolcs Szatmar Bereg County Hospital and University Teaching Hospital, Nyíregyháza, Hungary; Arizona Center for Cancer Care, Glendale, AZ; State Health Center, Budapest, Hungary; Samaritan Hematology and Oncology Associates, Corvalis, OR; Adelaide Cancer Centre, Kurralta Park, South Australia, Australia; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Uzsoki Hospital, Center of Oncoradiology, Budapest, Hungary; Szpital Rejonowy Dzienny Oddzial Chemioterapii, Racibórz, Poland; California Cancer Associates for Research and Excellence, Fresno, CA; Beaver Medical Group, Highland, CA; Hazard ARH Regional Medical Center, Hazard, KY; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation,
| | - LF Allen
- North Shore Hematology/Oncology, East Setaukut, NY; Breast Cancer Research Centre WA and Curtin University, Perth, Western Australia, Australia; Szabolcs Szatmar Bereg County Hospital and University Teaching Hospital, Nyíregyháza, Hungary; Arizona Center for Cancer Care, Glendale, AZ; State Health Center, Budapest, Hungary; Samaritan Hematology and Oncology Associates, Corvalis, OR; Adelaide Cancer Centre, Kurralta Park, South Australia, Australia; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Uzsoki Hospital, Center of Oncoradiology, Budapest, Hungary; Szpital Rejonowy Dzienny Oddzial Chemioterapii, Racibórz, Poland; California Cancer Associates for Research and Excellence, Fresno, CA; Beaver Medical Group, Highland, CA; Hazard ARH Regional Medical Center, Hazard, KY; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation,
| | - KL Tedesco
- North Shore Hematology/Oncology, East Setaukut, NY; Breast Cancer Research Centre WA and Curtin University, Perth, Western Australia, Australia; Szabolcs Szatmar Bereg County Hospital and University Teaching Hospital, Nyíregyháza, Hungary; Arizona Center for Cancer Care, Glendale, AZ; State Health Center, Budapest, Hungary; Samaritan Hematology and Oncology Associates, Corvalis, OR; Adelaide Cancer Centre, Kurralta Park, South Australia, Australia; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Uzsoki Hospital, Center of Oncoradiology, Budapest, Hungary; Szpital Rejonowy Dzienny Oddzial Chemioterapii, Racibórz, Poland; California Cancer Associates for Research and Excellence, Fresno, CA; Beaver Medical Group, Highland, CA; Hazard ARH Regional Medical Center, Hazard, KY; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation,
| | - R Agajanian
- North Shore Hematology/Oncology, East Setaukut, NY; Breast Cancer Research Centre WA and Curtin University, Perth, Western Australia, Australia; Szabolcs Szatmar Bereg County Hospital and University Teaching Hospital, Nyíregyháza, Hungary; Arizona Center for Cancer Care, Glendale, AZ; State Health Center, Budapest, Hungary; Samaritan Hematology and Oncology Associates, Corvalis, OR; Adelaide Cancer Centre, Kurralta Park, South Australia, Australia; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Uzsoki Hospital, Center of Oncoradiology, Budapest, Hungary; Szpital Rejonowy Dzienny Oddzial Chemioterapii, Racibórz, Poland; California Cancer Associates for Research and Excellence, Fresno, CA; Beaver Medical Group, Highland, CA; Hazard ARH Regional Medical Center, Hazard, KY; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation,
| | - I Lang
- North Shore Hematology/Oncology, East Setaukut, NY; Breast Cancer Research Centre WA and Curtin University, Perth, Western Australia, Australia; Szabolcs Szatmar Bereg County Hospital and University Teaching Hospital, Nyíregyháza, Hungary; Arizona Center for Cancer Care, Glendale, AZ; State Health Center, Budapest, Hungary; Samaritan Hematology and Oncology Associates, Corvalis, OR; Adelaide Cancer Centre, Kurralta Park, South Australia, Australia; University of Debrecen, Oncology Clinic, Debrecen, Hungary; Uzsoki Hospital, Center of Oncoradiology, Budapest, Hungary; Szpital Rejonowy Dzienny Oddzial Chemioterapii, Racibórz, Poland; California Cancer Associates for Research and Excellence, Fresno, CA; Beaver Medical Group, Highland, CA; Hazard ARH Regional Medical Center, Hazard, KY; Cancer Center of Adjara Autonomous Republic, Batumi, Georgia; Spectrum Pharmaceuticals, Irvine, CA; New York Oncology Hematology (US Oncology/McKesson Specialty Health), Albany, NY; The Oncology Institute of Hope and Innovation,
| |
Collapse
|
13
|
Herrero A, Pinto A, Colón-Bolea P, Casar B, Jones M, Agudo-Ibáñez L, Vidal R, Tenbaum SP, Nuciforo P, Valdizán EM, Horvath Z, Orfi L, Pineda-Lucena A, Bony E, Keri G, Rivas G, Pazos A, Gozalbes R, Palmer HG, Hurlstone A, Crespo P. Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes. Cancer Cell 2015; 28:170-82. [PMID: 26267534 DOI: 10.1016/j.ccell.2015.07.001] [Citation(s) in RCA: 103] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/03/2014] [Revised: 04/30/2015] [Accepted: 07/08/2015] [Indexed: 12/15/2022]
Abstract
Nearly 50% of human malignancies exhibit unregulated RAS-ERK signaling; inhibiting it is a valid strategy for antineoplastic intervention. Upon activation, ERK dimerize, which is essential for ERK extranuclear, but not for nuclear, signaling. Here, we describe a small molecule inhibitor for ERK dimerization that, without affecting ERK phosphorylation, forestalls tumorigenesis driven by RAS-ERK pathway oncogenes. This compound is unaffected by resistance mechanisms that hamper classical RAS-ERK pathway inhibitors. Thus, ERK dimerization inhibitors provide the proof of principle for two understudied concepts in cancer therapy: (1) the blockade of sub-localization-specific sub-signals, rather than total signals, as a means of impeding oncogenic RAS-ERK signaling and (2) targeting regulatory protein-protein interactions, rather than catalytic activities, as an approach for producing effective antitumor agents.
Collapse
Affiliation(s)
- Ana Herrero
- Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Consejo Superior de Investigaciones Científicas (CSIC), Universidad de Cantabria, Santander 39011, Spain
| | - Adán Pinto
- Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Consejo Superior de Investigaciones Científicas (CSIC), Universidad de Cantabria, Santander 39011, Spain
| | - Paula Colón-Bolea
- Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Consejo Superior de Investigaciones Científicas (CSIC), Universidad de Cantabria, Santander 39011, Spain
| | - Berta Casar
- Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Consejo Superior de Investigaciones Científicas (CSIC), Universidad de Cantabria, Santander 39011, Spain
| | - Mary Jones
- Faculty of Life Sciences, University of Manchester, Manchester M13 9PL, UK
| | - Lorena Agudo-Ibáñez
- Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Consejo Superior de Investigaciones Científicas (CSIC), Universidad de Cantabria, Santander 39011, Spain
| | - Rebeca Vidal
- Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Consejo Superior de Investigaciones Científicas (CSIC), Universidad de Cantabria, Santander 39011, Spain; Departamento de Fisiología y Farmacología, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III Universidad de Cantabria, Santander 39011, Spain
| | - Stephan P Tenbaum
- Stem Cells and Cancer Laboratory, Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona 08035, Spain
| | - Paolo Nuciforo
- Stem Cells and Cancer Laboratory, Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona 08035, Spain
| | - Elsa M Valdizán
- Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Consejo Superior de Investigaciones Científicas (CSIC), Universidad de Cantabria, Santander 39011, Spain; Departamento de Fisiología y Farmacología, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III Universidad de Cantabria, Santander 39011, Spain
| | | | - Laszlo Orfi
- Vichem Chemie Research Ltd., 1022 Budapest, Hungary; Department of Pharmaceutical Chemistry, Semmelweis University, 1092 Budapest, Hungary
| | | | - Emilie Bony
- Pharmacognosy Research Group, Louvain Drug Research Institute, Université Catholique de Louvain, 1200 Bruxelles, Belgium
| | - Gyorgy Keri
- Vichem Chemie Research Ltd., 1022 Budapest, Hungary; MTA-SE Pathobiochemistry Research Group, Department of Medical Chemistry, Semmelweis University, 1092 Budapest, Hungary
| | - Germán Rivas
- Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas, 28040 Madrid, Spain
| | - Angel Pazos
- Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Consejo Superior de Investigaciones Científicas (CSIC), Universidad de Cantabria, Santander 39011, Spain; Departamento de Fisiología y Farmacología, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III Universidad de Cantabria, Santander 39011, Spain
| | | | - Héctor G Palmer
- Stem Cells and Cancer Laboratory, Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona 08035, Spain
| | - Adam Hurlstone
- Departamento de Fisiología y Farmacología, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III Universidad de Cantabria, Santander 39011, Spain
| | - Piero Crespo
- Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Consejo Superior de Investigaciones Científicas (CSIC), Universidad de Cantabria, Santander 39011, Spain.
| |
Collapse
|
14
|
Ho H, Nemeth G, Ng Y, Pang E, Szantai-Kis C, Zsakai L, Breza N, Greff Z, Horvath Z, Pato J, Szabadkai I, Szokol B, Baska F, Orfi L, Ullrich A, Keri G, Chua B. Developing FGFR4 Inhibitors As Potential Anti-Cancer Agents Via In Silico Design, Supported by In Vitro and Cell-Based Testing. Curr Med Chem 2013. [DOI: 10.2174/09298673113208880013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
15
|
Exner R, Sachsenmaier M, Horvath Z, Stift A. Incidental appendectomy--standard or unnecessary additional trauma in surgery for colorectal cancer? A retrospective analysis of histological findings in 380 specimens. Colorectal Dis 2012; 14:1262-6. [PMID: 22230025 DOI: 10.1111/j.1463-1318.2012.02933.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
BACKGROUND Incidental appendectomy is a frequent but non-standard procedure during surgery for colorectal cancer. Incidental appendectomy during colorectal resections is performed at the discretion of the operating surgeon. METHOD This retrospective study used data from 1352 consecutive patients who underwent surgery for colorectal cancer between 1993 and 2009 at the Medical University of Vienna. The authors evaluated histopathological results of appendices removed incidentally. In addition, complications and costs of the additional intervention were analyzed. RESULTS Appendectomy had been performed in 314 (23.22%) patients because of appendicitis. Incidental appendectomy had been performed in 380 (28.11%) patients: 86 (22.63%) had a histologically completely normal appendix, a pathologic alteration was found in 289 (76.05%) and a neoplasm was found in seven (1.84%). No complications occurred from the additional surgical procedure. The costs and time effort were negligible. CONCLUSION Incidental appendectomy is a safe procedure and can be integrated into surgery for colorectal carcinoma to avoid future complications. Pathological findings of the appendix, including neoplasm, are frequent but the clinical relevance remains questionable.
Collapse
Affiliation(s)
- R Exner
- Department of General Surgery, Medical University of Vienna, Vienna, Austria.
| | | | | | | |
Collapse
|
16
|
Savolt A, Peley G, Toth L, Matrai Z, Polgar C, Horvath Z, Szabo E, Borbely K. 548 FDG-PET/CT Follow-up of Patients with Sentinel Node-Positive Breast Cancer After Axillary Nodal Irradiation Without Completion Axillary Dissection. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)70613-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
17
|
Kaemmerer H, Horvath Z, Lee JW, Kaspereit M, Arnell R, Hedberg M, Herschend B, Jones MJ, Larson K, Lorenz H, Seidel-Morgensten A. Separation of Racemic Bicalutamide by an Optimized Combination of Continuous Chromatography and Selective Crystallization. Org Process Res Dev 2011. [DOI: 10.1021/op200136z] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
| | | | | | | | - Robert Arnell
- AstraZeneca R&D Södertälje, Pharmaceutical Development, 15185 Södertälje, Sweden
| | - Martin Hedberg
- AstraZeneca R&D Södertälje, Pharmaceutical Development, 15185 Södertälje, Sweden
| | - Björn Herschend
- AstraZeneca R&D Södertälje, Pharmaceutical Development, 15185 Södertälje, Sweden
| | - Matthew J. Jones
- AstraZeneca R&D Södertälje, Pharmaceutical Development, 15185 Södertälje, Sweden
| | - Kerstin Larson
- AstraZeneca R&D Södertälje, Pharmaceutical Development, 15185 Södertälje, Sweden
| | | | | |
Collapse
|
18
|
Horvath Z, Sajo IE, Stoll K, Menyhard A, Varga J. The effect of molecular mass on the polymorphism and crystalline structure of isotactic polypropylene. EXPRESS POLYM LETT 2010. [DOI: 10.3144/expresspolymlett.2010.15] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
19
|
Hegymegi-Barakonyi B, Szekely R, Varga Z, Kiss R, Borbely G, Nemeth G, Banhegyi P, Pato J, Greff Z, Horvath Z, Meszaros G, Marosfalvi J, Eros D, Szantai-Kis C, Breza N, Garavaglia S, Perozzi S, Rizzi M, Hafenbradl D, Ko M, Av-Gay Y, Klebl B, Orfi L, Keri G. Signalling Inhibitors Against Mycobacterium tuberculosis – Early Days of a New Therapeutic Concept in Tuberculosis. Curr Med Chem 2008; 15:2760-70. [DOI: 10.2174/092986708786242886] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
20
|
Hejjas K, Vas J, Topal J, Szantai E, Ronai Z, Szekely A, Kubinyi E, Horvath Z, Sasvari-Szekely M, Miklosi A. Association of polymorphisms in the dopamine D4 receptor gene and the activity-impulsivity endophenotype in dogs. Anim Genet 2007; 38:629-33. [PMID: 17986156 DOI: 10.1111/j.1365-2052.2007.01657.x] [Citation(s) in RCA: 84] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
A variable number of tandem repeats (VNTR) polymorphism in exon 3 of the human dopamine D4 receptor gene (DRD4) has been associated with attention deficit hyperactivity disorder (ADHD). Rodents possess no analogous repeat sequence, whereas a similar tandem repeat polymorphism of the DRD4 gene was identified in dogs, horses and chimpanzees. Here, we present a genetic association study of the DRD4 VNTR and the activity-impulsivity dimension of the recently validated dog-ADHD Rating Scale. To avoid false positives arising from population stratification, a single breed of dogs (German shepherd) was studied. Two DRD4 alleles (referred to as 2 and 3a) were detected in this breed, and genotype frequencies were in Hardy-Weinberg equilibrium. For modelling distinct environmental conditions, 'pet' and 'police' German shepherds were characterized. Police German shepherds possessing at least one 3a allele showed significantly higher scores in the activity-impulsivity dimension of the dog-ADHD Rating Scale than dogs without this allele (P = 0.0180). This difference was not significant in pet German shepherds. To the best of our knowledge, this is the first report of an association between a candidate gene and a behaviour trait in dogs, and it reinforces the functional role of DRD4 exon 3 polymorphism.
Collapse
Affiliation(s)
- K Hejjas
- Department of Medical Chemistry, Molecular Biology and Pathobiochemistry, Semmelweis University, Puskin u. 9, Budapest, H-1088, Hungary
| | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Horvath Z, Czeglédi F, Ganofszky E, Hitre E, Juhos E, Szabo E, Szabo E, Peter I, Bak M, Lang I. 2078 POSTER Retrospective analysis of routine preoperative chemotherapy on effectivity and survival of 61 inflammatory breast cancer patients. EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)70840-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
22
|
Horvath Z, Saiko P, Illmer C, Madlener S, Hoechtl T, Bauer W, Erker T, Jaeger W, Fritzer-Szekeres M, Szekeres T. Resveratrol, an ingredient of wine, acts synergistically with Ara-C and tiazofurin in HL-60 human promyelocytic leukemia cells. Nucleosides Nucleotides Nucleic Acids 2007; 25:1019-24. [PMID: 17065057 DOI: 10.1080/15257770600890574] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
Resveratrol (RV), a naturally occurring stilbene derivative, is a potent free radical scavenger causing a number of biochemical and antineoplastic effects. It was shown to induce differentiation and apoptosis in leukemia cells and was also identified as an inhibitor of ribonucleotide reductase (RR), a key enzyme of DNA synthesis. In this study, we report about the biochemical effects of RV in HL-60 human promyelocytic leukemia cells. RV effectively inhibited in situ RR activity. Furthermore, incubation of HL-60 cells with RV significantly decreased intracellular dCTP, dTTP, dATP and dGTP concentrations. In growth inhibition and clonogenic assays, RV acted synergistically with both Ara-C and tiazofurin in HL-60 cells. We conclude that RV could become a viable candidate as one compound in the combination chemotherapy of leukemia and therefore deserves further in vitro and in vivo testing.
Collapse
Affiliation(s)
- Z Horvath
- Clinical Institute of Medical and Chemical Laboratory Diagnostics, General Hospital of Vienna, Medical University of Vienna, Vienna, Austria.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Saiko P, Horvath Z, Murias M, Handler N, Jaeger W, Erker T, Fritzer-Szekeres M, Szekeres T. Antitumor effects of 3,3',4,4',5,5'-hexahydroxystilbene in HL-60 human promyelocytic leukemia cells. Nucleosides Nucleotides Nucleic Acids 2007; 25:1013-7. [PMID: 17065056 DOI: 10.1080/15257770600890624] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
Resveratrol (3,4',5-trihydroxystilbene, RV) exerts remarkable cytostatic and cytotoxic effects against a multitude of human cancer cell lines. Since the introduction of additional hydroxyl groups was supposed to increase the biological activity of RV, we have synthesized a number of polyhydroxylated stilbene analogues as potential antitumor agents. In this study, the activity of 3,3',4,4',5,5'-hexahydroxystilbene (M8) was investigated in HL-60 human promyelocytic leukemia cells. Employing a growth inhibition assay, incubation with M8 and RV resulted in IC50 values of 6.25 and 12 microM, respectively. Using a specific Hoechst/propidium iodide double staining method, we found that M8 was able to induce apoptosis in concentrations significantly lower than those of RV. In addition, M8 arrested cells in the S phase and totally depleted cells in the G2-M phase of the cell cycle (143% and 0% of control after treatment with 12.5 microM M8, respectively). We therefore believe that this promising agent deserves further preclinical and in vivo testing.
Collapse
Affiliation(s)
- P Saiko
- Clinical Institute of Medical and Chemical Laboratory Diagnostics, General Hospital of Vienna, Medical University of Vienna, Vienna, Austria.
| | | | | | | | | | | | | | | |
Collapse
|
24
|
Keri G, Orfi L, Eros D, Hegymegi-Barakonyi B, Szantai-Kis C, Horvath Z, Waczek F, Marosfalvi J, Szabadkai I, Pato J, Greff Z, Hafenbradl D, Daub H, Muller G, Klebl B, Ullrich A. Signal Transduction Therapy with Rationally Designed Kinase Inhibitors. ACTA ACUST UNITED AC 2006. [DOI: 10.2174/157436206775269190] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
25
|
Saiko P, Bauer W, Horvath Z, Hoechtl T, Grusch M, Illmer C, Madlener S, Krupitza G, Mader RM, Schott H, Fritzer-Szekeres M, Szekeres T. Cytotoxic and apoptotic effects of novel heterodinucleoside phosphates consisting of 5-fluorodeoxyuridine and Ara-C in human cancer cell lines. Nucleosides Nucleotides Nucleic Acids 2005; 23:1507-11. [PMID: 15571287 DOI: 10.1081/ncn-200027723] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
In search for possible alternatives in the treatment of human malignancies we investigated several new heterodinucleoside phosphates consisting of 5-Fluorodeoxyuridine (5-FdUrd) and Arabinofuranosylcytosine (Ara-C). We show that all dimers tested inhibited the number of colonies of CCL228, CCL227, 5-FU resistant CCL227 and HT-29 human colon tumor cells with IC50 values ranging from 0.65 to 1 nM. Dimer # 2 inhibited the number of sensitive and Ara-C resistant H9 human lymphoma cells with IC50 values ranging from 200 to 230 nM. Since no significant difference in the cytotoxicity of the dimers could be observed between sensitive and resistant cells, these compounds might be used in the treatment of 5-FU and Ara-C resistant tumors.
Collapse
Affiliation(s)
- P Saiko
- Clinical Institute of Med. and Chem. Laboratory Diagnostics, University of Vienna, Vienna, Austria
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Bauer W, Horvath Z, Höchtl T, Saiko P, Karl D, Fritzer-Szekeres M, Szekeres T. Amidox, an inhibitor of ribonucleotide reductase, potentiates the action of Ara-C in HL-60 human promyelocytic leukemia cells. Nucleosides Nucleotides Nucleic Acids 2005; 23:1541-4. [PMID: 15571294 DOI: 10.1081/ncn-200027766] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Amidox (3,4-dihydroxybenzamidoxime), a new polyhydroxy-substituted benzoic acid derivative, is a potent inhibitor of the enzyme ribonucleotide reductase (RR), which catalyses the de novo synthesis of DNA. RR is considered to be an excellent target for cancer chemotherapy. In the present study we investigated the antineoplastic effects of Amidox alone and in combination with Arabinofuranosylcytosine (Ara-C) in HL-60 human promyelocytic leukemia cells. In growth inhibition experiments Amidox yielded an IC50 of 30 microM, colony formation was inhibited at an IC50 of 20 microM as determined by a soft agar assay. Exposure of the cells to 75 and 100 microM Amidox for 24 hours was shown to significantly decrease intracellular dCTP, dGTP and dATP pools, whereas dTTP concentration increased, as determined by HPLC. The combination of Amidox with Ara-C yielded more than additive cytotoxic effects both in growth inhibition assays and in soft agar assays. We could show that--after preincubating the cells with 75 and 100 microM Amidox and subsequent exposure to Ara-C--intracellular Ara-CTP levels increased by 576% and 1143%, respectively. In conclusion, Amidox might offer an additional option for the treatment of leukemia and thus be further investigated in vitro and in vivo.
Collapse
Affiliation(s)
- W Bauer
- Clinical Institute of Medical and Chemical Laboratorydiagnostics, University of Vienna, Vienna, Austria
| | | | | | | | | | | | | |
Collapse
|
27
|
Horvath Z, Handler N, Saiko P, Madlener S, Illmer C, Murias M, Fritzer-Szekeres M, Erker T, Jäger W, Szekeres T. 574 Comparative study of anticancer and apoptosis-inducing activity of stilbene derivatives in HL-60 human promyelocytic leukemia cells. EJC Suppl 2004. [DOI: 10.1016/s1359-6349(04)80582-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
28
|
Hitre E, Adleff V, Budai B, Szabó E, Horvath Z, Lang I, Czeglédi F, Orosz Z, Gazdag A, Kralovanszky J. Thymidylate synthase (TS) gene polymorphisms affect disease free- (DFS) and overall (OS) survival of colorectal cancer (CRC) patients treated with adjuvant 5-fluorouracil-folinic acid (FUFA). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3581] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- E. Hitre
- National Institute of Oncology, Budapest, Hungary
| | - V. Adleff
- National Institute of Oncology, Budapest, Hungary
| | - B. Budai
- National Institute of Oncology, Budapest, Hungary
| | - E. Szabó
- National Institute of Oncology, Budapest, Hungary
| | - Z. Horvath
- National Institute of Oncology, Budapest, Hungary
| | - I. Lang
- National Institute of Oncology, Budapest, Hungary
| | - F. Czeglédi
- National Institute of Oncology, Budapest, Hungary
| | - Z. Orosz
- National Institute of Oncology, Budapest, Hungary
| | - A. Gazdag
- National Institute of Oncology, Budapest, Hungary
| | | |
Collapse
|
29
|
Lang I, Hitre E, Horvath Z. Two-year follow up results of a population-based prospective case control study of 143 stage IV colorectal cancer (CRC) patients treated with 2 nd line irinotecan (iri) outside of clinical trial. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3687] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- I. Lang
- National Institute of Oncology, Budapest, Hungary
| | - E. Hitre
- National Institute of Oncology, Budapest, Hungary
| | - Z. Horvath
- National Institute of Oncology, Budapest, Hungary
| |
Collapse
|
30
|
Horvath Z, Barnes RM. Carboxymethylated polyethylenimine-polymethylenepolyphenylene isocyanate chelating ion exchange resin preconcentration for inductively coupled plasma spectrometry. Anal Chem 2002. [DOI: 10.1021/ac00298a018] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
31
|
|
32
|
Fritzer-Szekeres M, Luxbacher C, Horvath Z, Grusch M, Krupitza G, Elford HL, Szekeres T. Apoptosis-inducing cleavage of caspases by trimidox, an inhibitor of ribonucleotide reductase. Adv Exp Med Biol 2002; 486:125-30. [PMID: 11783468 DOI: 10.1007/0-306-46843-3_25] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Affiliation(s)
- M Fritzer-Szekeres
- Clin. Institute for Med. & Chem. Laboratory Diagnostics, Medical School, University of Vienna, Austria
| | | | | | | | | | | | | |
Collapse
|
33
|
Balás I, Llumiguano C, Horvath Z, Kovér F, Dóczi TP. [MRI guided stereotactic thalamotomy for the treatment of the neurogenic pain]. Rev Neurol 2000; 31:531-3. [PMID: 11055055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/18/2023]
Abstract
INTRODUCTION Medial thalamotomy is one of the first stereotactic operations to have been used for neurogenic pain, has a low complication rate and no risk of the development of iatrogenic neurogenic pain. It represents selective local relief for all types of pain, without causing somatosensorial deficit. PATIENTS AND METHODS We did 39 posteromedial thalamotomies in patients with persistent intractable pain due to various disorders. The pain was assessed pre- and postoperatively on the VAS (Visual Analogic Scale). RESULTS Half of the patients operated on had relief of pain after thalamotomy. In 84% (n = 39) of our cases this relief occurred on the second day, in 70% (n = 35) after three months, in 63% (n = 27) after six months, in 64% (n = 25) after nine months, in 62% (n = 23) of the patients after 12 months, and in 62% (n = 22) after 24 months. Three patients had temporary complications and one a permanent complication, but this did not make him an invalid. CONCLUSION Posteromedial stereotactic thalamotomy under MR guidance can provide safe, effective treatment for persistent, intractable pain.
Collapse
Affiliation(s)
- I Balás
- Departamento de Neurocirugía, Facultad de Medicina, Universidad de Pecs, Hungría
| | | | | | | | | |
Collapse
|
34
|
Horvath Z, Lasztity A, Zih-Perenyi K, Levai A. Optimization of Flow Injection On-Line Microcolumn Preconcentration of Ultratrace Elements in Environmental Samples prior to Their Spectrochemical Determination. Microchem J 1996; 54:391-401. [PMID: 8979954 DOI: 10.1006/mchj.1996.0116] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The preconcentration of some elements such as Cd, Co, Ni, and V(IV) was modeled in the presence of complexing agents such as citrate and oxalate at high Ca, Mg, and sulfate concentrations on iminodiacetic acid/ethyl cellulose (IDAEC), a chelating cellulose. The effect of the species present in the solution was studied after construction of the species distribution curves using critical, estimated, and measured stability constants. The stability constants of the IDAEC chelates were determined potentiometrically. The constants were calculated or estimated using computer programs. The diagrams calculated in homogeneous media were used for optimization of the flow injection on-line preconcentration for analysis of ultratrace metals in the highly mineralized water "Hunyadi."
Collapse
Affiliation(s)
- Z Horvath
- Institute of Inorganic and Analytical Chemistry, Eotvos L. University, Budapest 112, H-1518, Hungary
| | | | | | | |
Collapse
|
35
|
Jandó G, Carpi D, Kandel A, Urioste R, Horvath Z, Pierre E, Vadi D, Vadasz C, Buzsáki G. Spike-and-wave epilepsy in rats: sex differences and inheritance of physiological traits. Neuroscience 1995; 64:301-17. [PMID: 7700522 DOI: 10.1016/0306-4522(94)00329-4] [Citation(s) in RCA: 59] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Spontaneously occurring spike-and-wave patterns were examined in seven to eight-month-old rats of the inbred Fischer 344 and Brown Norway strains and their F1 and F2 hybrids. Neocortical activity and movement were monitored for 12 night h. Spike-and-wave episodes were identified by a three-layer back-propagation neural network. The incidence, average duration and total duration of spike-and-wave episodes were significantly higher in F1 males and F2 hybrids than in the parental strains. Male rats of the Brown Norway strain had significantly more and longer episodes than females, whereas no sex differences were present in Fischer rats. The average intraepisodic frequency of spike-and-wave patterns was significantly lower in Fischer rats than in the other groups and significantly higher in males than females. Tremor (myoclonic movements) associated with spike-and-wave episodes was absent or of very small amplitude in Fischer rats but frequent and of large amplitude in Brown Norway rats and their F1 and F2 descendants. Most of the interstrain differences were limited to male rats. Spike-and-wave episodes recurred at predictable short-term (10-30 s) and long-term (15-30 min) periods. The long-term oscillation corresponded to a similar fluctuation of motor activity. The maximum probability of spike-and-wave patterns occurred at a relatively narrow range of delta power (0-3.1 Hz) of the background EEG activity. Systemic administration of the adrenergic alpha-2 agonist, clonidine, increased the incidence of spike-and-wave episodes several-fold. The total duration of spike-and-wave episodes in the clonidine sessions (15 min) and night sessions (12 h test) correlated significantly. We suggest that several genes interact with maturational, environmental and endocrine factors, resulting in sex differences, and produce the variety of EEG and behavioral findings encountered. In addition, we submit that the clonidine test may be useful in genetic investigations of human absence epilepsies. The findings of this work demonstrate that genetic manipulation of rodents is a promising method for producing analogous models for the various forms of human absence epilepsies.
Collapse
Affiliation(s)
- G Jandó
- Center for Molecular and Behavioural Neuroscience, Rutgers, State University of New Jersey, Newark 07102, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Sadile AG, Neugebauer A, Morelli F, Horvath Z, Buzsàki G, Giuditta A. Distributed changes in rat brain DNA synthesis with long-term habituation and potentiation of the perforant path-granule cell synapse. Behav Brain Res 1991; 46:83-94. [PMID: 1786115 DOI: 10.1016/s0166-4328(05)80099-3] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The involvement of brain deoxyribonucleic acid (DNA) synthesis in adaptive neural events was studied in the adult rat during long-term habituation (LTH) or potentiation (LTP) of the perforant path-granule cell synapse. Male Long-Evans rats were given 50 muCi [3H]thymidine intraventricularly under urethane anesthesia. Soon thereafter, field excitatory postsynaptic potential (EPSP) slope and population spike were monitored from the right dentate gyrus before and at various times (5, 10, 15, 60 min) following the delivery to the ipsilateral perforant bundle of a low frequency (LFS: 1.0 Hz, 160 s) or a high-frequency train (HFS: 400 Hz, 200 ms), repeated once after 5 min. Unstimulated implanted rats served as controls. DNA synthesis was evaluated by the incorporation of the radioactive precursor into DNA of several brain areas at the end of a 1 h incorporation period. In CA1, LTH and LTP increased DNA synthesis by 30% on the stimulated side. In the entorhinal cortex, LTH but not LTP increased DNA synthesis (by 30%) on the stimulated side. Conversely, in the frontal cortex, LTP but not LTH increased DNA synthesis (by 100%) on both sides. Long-lasting changes in synaptic efficacy covaried non-linearly with DNA synthesis in mono- and polysynaptically stimulated hippocampal regions, and in functionally associated neocortical areas. The co-variations of population spike amplitude were positive for LTH and negative for LTP in the dentate gyrus and frontal cortex of both sides, and in CA3/CA1 of the stimulated side, indicating higher DNA synthesis at lower values of LTH and LTP, and viceversa. Further, regional cross-correlation analyses revealed a high degree of synchronization among brain sites, following low- or high-frequency train pulses, indicating that (i) extra-target sites participate on the stimulated and on the contralateral side, and (ii) small distributed changes take place across the sampled neural networks. A modulatory role of information flow on brain DNA synthesis is inferred to take place in a diffuse, distributed manner.
Collapse
Affiliation(s)
- A G Sadile
- Dipt. Fisiologia Umana e Funzioni Biologiche Integrate F. Bottazzi, Naples, Italy
| | | | | | | | | | | |
Collapse
|
37
|
|
38
|
Abstract
A systematic psychiatric evaluation was performed on 100 consecutive patients attending a multiple sclerosis clinic. Forty-two percent of the patients had lifetime history of depression, and 13% fulfilled criteria for manic-depressive illness. Only 28% of the patients had no psychiatric diagnosis. The relationship of psychiatric disorder to neurologic dysfunction and other aspects of multiple sclerosis are presented. Clinical and theoretical implications of these findings are discussed.
Collapse
|
39
|
Abstract
There is a high prevalence of affective illness, both depression and bipolar disorder, in patients with multiple sclerosis. In this study, the family history method was used to assess the prevalence of affective illness in first-degree relatives of patients with multiple sclerosis. There was not an excess of affective illness in the relatives suggesting that affective disorder associated with multiple sclerosis does not have a familial pattern similar to primary affective disorder. Clinical and theoretical implications of these findings are discussed.
Collapse
|
40
|
|
41
|
Lias SG, Ausloos P, Horvath Z. Charge transfer reactions in alkane and cycloalkane systems. Estimated ionization potentials. INT J CHEM KINET 1976. [DOI: 10.1002/kin.550080508] [Citation(s) in RCA: 29] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|